TY - JOUR
T1 - Time below range alone is insufficient to identify severe hypoglycaemia risk in type 1 diabetes—the critical role of hypoglycaemia awareness
T2 - results from the SFDT1 study
AU - Canha, Dulce
AU - Choudhary, Pratik
AU - Cosson, Emmanuel
AU - Banu, Isabela
AU - Barraud, Sara
AU - Valéro, René
AU - Ronci, Nathalie
AU - Delenne, Blandine
AU - Dufaitre, Lise
AU - Vidal-Trecan, Tiphaine
AU - Schaepelynck, Pauline
AU - Sanz, Caroline
AU - Tatulashvili, Sopio
AU - Aguayo, Gloria A.
AU - Fagherazzi, Guy
AU - Riveline, Jean Pierre
N1 - Funding:
DC is supported by the Luxembourg National Research Fund
through grant no. PRIDE21/16749720. This work was made possi-
ble thanks to institutional support from the Fondation Francophone
pour la Recherche sur le Diabète (FFRD), the Société Francophone
du Diabète (SFD) and the Luxembourg Institute of Health, as well
as from the following partners: Breakthrough T1D/JDRF; Aide aux
Jeunes Diabétiques (AJD); Fédération Française des Diabétiques;
Lilly; Abbott; Air Liquide Healthcare; Novo Nordisk; Sanofi; Insulet;
Medtronic; Dexcom; Ypsomed; Lifescan; and Sur les Pas de So. The
study sponsors/funders were not involved in the design of the study, the
collection, analysis and interpretation of data, writing the report, and
did not impose any restrictions regarding the publication of the report.
For the purpose of open access, and in fulfilment of the obligations
arising from the grant agreement, the author has applied a Creative
Commons Attribution 4.0 International (CC BY 4.0) license to any
Author Accepted Manuscript version arising from this submission.
Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - AIMS/HYPOTHESIS: Severe hypoglycaemia events (SHE) remain frequent in people with type 1 diabetes despite advanced diabetes technologies. We examined whether time below range (TBR) 3.9 mmol/l (70 mg/dl; TBR70) or 3.0 mmol/l (54 mg/dl; TBR54) is associated with future SHE risk and whether impaired awareness of hypoglycaemia (IAH) modifies this relationship.METHODS: We analysed data from participants in the Study of the French-speaking Society of Type 1 Diabetes (SFDT1) who used continuous glucose monitoring. IAH was assessed using the Gold Score (≤2, no IAH; 3, undetermined; ≥4, IAH). SHE frequency was self-reported 12 months after inclusion. We analysed associations between TBR and SHE using logistic regression models adjusted for age, sex, social vulnerability and insulin treatment, including TBR-IAH interactions. We performed spline analyses to explore non-linear patterns.RESULTS: One-year incidence of SHE was 11.7% among 848 participants (mean ± SD age 41.6 ± 13.3 years; 53.8% female sex, HbA
1c 57.2 ± 10.9 mmol/mol [7.4 ± 1.0%]). Incidence by TBR70 was 12.1% for ≤1%, 10.2% for 1.1-3.9%, 10.6% for 4-6%, and 14.6% for >6%. Only those with TBR70 >6% and IAH had a significantly higher SHE risk (OR 3.32 [95% CI 1.40, 7.82]) compared with TBR70 ≤1% and no IAH. For TBR54, SHE incidence was 11.0% and 13.3% for categories <1% and ≥1%, respectively. Similarly, only individuals with TBR54≥1% and IAH had increased SHE risk (OR 2.99 [95% CI 1.46, 5.92]). Spline analysis showed low, stable SHE risk across TBR70 values in participants without IAH, with a non-linear pattern only in those with IAH.
CONCLUSIONS/INTERPRETATION: TBR alone is not discriminative for high-risk SHE but combining TBR with hypoglycaemia awareness status identifies those at the highest risk for both TBR70 and TBR54.TRIAL REGISTRATION: ClinicalTrials.gov NCT04657783.
AB - AIMS/HYPOTHESIS: Severe hypoglycaemia events (SHE) remain frequent in people with type 1 diabetes despite advanced diabetes technologies. We examined whether time below range (TBR) 3.9 mmol/l (70 mg/dl; TBR70) or 3.0 mmol/l (54 mg/dl; TBR54) is associated with future SHE risk and whether impaired awareness of hypoglycaemia (IAH) modifies this relationship.METHODS: We analysed data from participants in the Study of the French-speaking Society of Type 1 Diabetes (SFDT1) who used continuous glucose monitoring. IAH was assessed using the Gold Score (≤2, no IAH; 3, undetermined; ≥4, IAH). SHE frequency was self-reported 12 months after inclusion. We analysed associations between TBR and SHE using logistic regression models adjusted for age, sex, social vulnerability and insulin treatment, including TBR-IAH interactions. We performed spline analyses to explore non-linear patterns.RESULTS: One-year incidence of SHE was 11.7% among 848 participants (mean ± SD age 41.6 ± 13.3 years; 53.8% female sex, HbA
1c 57.2 ± 10.9 mmol/mol [7.4 ± 1.0%]). Incidence by TBR70 was 12.1% for ≤1%, 10.2% for 1.1-3.9%, 10.6% for 4-6%, and 14.6% for >6%. Only those with TBR70 >6% and IAH had a significantly higher SHE risk (OR 3.32 [95% CI 1.40, 7.82]) compared with TBR70 ≤1% and no IAH. For TBR54, SHE incidence was 11.0% and 13.3% for categories <1% and ≥1%, respectively. Similarly, only individuals with TBR54≥1% and IAH had increased SHE risk (OR 2.99 [95% CI 1.46, 5.92]). Spline analysis showed low, stable SHE risk across TBR70 values in participants without IAH, with a non-linear pattern only in those with IAH.
CONCLUSIONS/INTERPRETATION: TBR alone is not discriminative for high-risk SHE but combining TBR with hypoglycaemia awareness status identifies those at the highest risk for both TBR70 and TBR54.TRIAL REGISTRATION: ClinicalTrials.gov NCT04657783.
KW - Continuous glucose monitoring
KW - Impaired awareness of hypoglycaemia
KW - Severe hypoglycaemia
KW - Time below range
KW - Type 1 diabetes
KW - Humans
KW - Middle Aged
KW - Awareness
KW - Blood Glucose/metabolism
KW - Risk Factors
KW - Male
KW - Hypoglycemia/epidemiology
KW - Diabetes Mellitus, Type 1/drug therapy
KW - Blood Glucose Self-Monitoring
KW - Adult
KW - Female
KW - Hypoglycemic Agents/therapeutic use
KW - Insulin/therapeutic use
UR - https://www.scopus.com/pages/publications/105015564787
UR - https://pubmed.ncbi.nlm.nih.gov/40924111/
U2 - 10.1007/s00125-025-06536-x
DO - 10.1007/s00125-025-06536-x
M3 - Article
C2 - 40924111
AN - SCOPUS:105015564787
SN - 0012-186X
VL - 68
SP - 2719
EP - 2731
JO - Diabetologia
JF - Diabetologia
IS - 12
ER -